Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S. Wang, Amir T. Fathi, Ghayas C. Issa et al.|The Lancet Oncology|2024Cited by 106
Ziftomenib in Relapsed or Refractory <i>NPM1</i> -Mutated AMLJordi Esteve Reyner, Pau Montesinos, James M. Foran et al.|Journal of Clinical Oncology|2025Cited by 33
Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007Ghayas C. Issa, Eunice S. Wang, Suresh Kumar Balasubramanian et al.|Blood|2025Cited by 7
AML-732: Ziftomenib Combined With Intensive Induction Chemotherapy (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia (AML): Updated Phase 1a/b Results From KOMET-007Amer M. Zeidan, Harry P. Erba, Eunice S. Wang et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 3
POSTER: AML-732 Ziftomenib Combined With Intensive Induction Chemotherapy (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia (AML): Updated Phase 1a/b Results From KOMET-007Amer M. Zeidan, Harry P. Erba, Eunice S. Wang et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0